Search company, investor...
HistoIndex company logo

HistoIndex

histoindex.com

About HistoIndex

HistoIndex is an AI-based digital pathology solutions company. The company provides optical medical imaging systems and services to aid pathologists in diagnostics, clinical trials, and research studies for the assessment and staging of diseases. It is based in Singapore.

Headquarters Location

79 Ayer Rajah Crescent 04-05 JTC Launchpad

Singapore, 139955,

Singapore

Missing: HistoIndex's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: HistoIndex's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing HistoIndex

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

HistoIndex is included in 1 Expert Collection, including Clinical Encounter Tech.

C

Clinical Encounter Tech

625 items

HistoIndex Patents

HistoIndex has filed 1 patent.

patents chart

Application Date

Grant Date

Title

Related Topics

Status

2/25/2013

Microscopy, Digital photography, Histology, Image processing, Geometrical optics

Application

Application Date

2/25/2013

Grant Date

Title

Related Topics

Microscopy, Digital photography, Histology, Image processing, Geometrical optics

Status

Application

Latest HistoIndex News

PLX065 reduces liver fat content, prevents worsening of fibrosis in NASH

Nov 11, 2022

Source: Harrison SA, et al. PLX065 (deuterium-stabilized r-enantiomer of pioglitazone) reduces liver fat content and improves liver histology without PPAR gamma-mediated side effects in patients with NASH: Analysis of a 36-week placebo-controlled phase 2 trial (DESTINY1). Disclosures: Harrison reports financial relationships with 89 Bio, AgomAB, Akero Therapeutics Inc., Alentis Therapeutics AG, Alimentiv Inc., Altimmune, Arrowhead, Axcella Health Inc., Boston Pharmaceuticals, B Riley FBR Inc., BVF Partners LP, Cohbar Inc., Canfite, Corcept Therapeutics Inc., Chronwell, CiVi, Cymabay Therapeutics Inc., Echosens North America Inc., Enyo Pharma S.A., Fibronostics, Foresite Labs LLC, Fortress Biotech Inc., Galectin Therapeutics Inc., Galmed Research & Dev. LTD, Gilead Sciences, Genfit Corp., GNS, Hepion Pharmaceuticals Inc., Hightide Therapeutics Inc., HistoIndex PTE LTD, Indalo, Inipharm, Intercept Pharmaceuticals Inc., lonis, Kowa Research Institute Inc., Madrigal Pharmaceuticals Inc., Medpace Inc., Metacrine Inc., Microba, NGM Biopharmaceuticals Inc., Northsea Therapeutics B.V., Novartis Pharmaceuticals, Novo Nordisk, Nutrasource, PathAI, Perspectum Diagnostics, Piper Sandler, Poxel, Prometic, Pharma SMT LTD, Ridgeline, Sagimet Biosciences, Sonic Incytes Medical Corp., Terns Inc., Theratechnologies and Viking Therapeutics Inc. ADD TOPIC TO EMAIL ALERTS Receive an email when new articles are posted on Please provide your email address to receive an email when new articles are posted on . Subscribe ADDED TO EMAIL ALERTS Back to Healio We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com . Back to Healio WASHINGTON — PXL065, a novel PPAR gamma-sparing chemical entity of pioglitazone, reduced liver fat content with no dose-dependent effect on weight gain in patients with nonalcoholic steatohepatitis, according to late-breaking data. “ Pioglitazone has been extensively studied for many years. There have been at least six biopsy trials of varying durations, varying numbers of patients included in the trial, each showing histopathological and biochemical benefit,” Stephen A. Harrison, MD, FAASLD, medical director for Pinnacle Clinical Research and president of Summit Clinical Research in San Antonio, said at The Liver Meeting. “Pioglitazone has been extensively studied for many years. … There have been at least six biopsy trials of varying durations, varying numbers of patients included in the trial, each showing histopathological and biochemical benefit,” Stephen A. Harrison, MD, FAASLD, said.Source: Adobe Stock “It’s been shown that the S enantiomer [in pioglitazone] is what is linked to the adverse event profile of weight gain, fluid retention and other adverse events,” he said. “PXL065 is a deuterium stabilized single stereoisomer that selectively mediates the non-PPAR gamma effects of pioglitazone but retains efficacy in preclinical NASH models with no significant weight gain or fluid retention.” In the DESTINY1 phase 2a study, Harrison and colleagues aimed to validate the use of PXL065 in 117 patients with noncirrhotic NASH, who were randomized to receive daily oral doses of PLX065 7.5 mg, 15 mg, 22.5 mg or placebo for 36 weeks. The primary endpoint was relative percent change in liver fat content assessed by MRI-proton density fat fraction, and other outcomes of interest included histology from paired liver biopsies, liver enzymes, biomarkers of fibrosis , adiponectin, lipids, glycemic parameters and safety and tolerability. According to results, all PLX065-treated patients achieved the primary endpoint and up to 40% achieved a 30% relative reduction in liver fat content. Harrison also noted improvements in alanine aminotransferase, fibrosis biomarkers and fibrosis risk scores. Histology analysis revealed that 35% to 50% of patients treated with PXL065 achieved fibrosis improvement compared with 17% of patients treated with placebo. NASH resolution and fibrosis improvement occurred in 15% to 33% of treated patients compared with 13% of placebo. Glucose control also improved and placebo-adjusted change in HbA1C reached –0.41% (baseline 6.07%-6.25%) with no dose-dependent effect on body weight. “There were significant reductions in liver fat content achieving the primary endpoint an all three doses. ... Noninvasive assessments of inflammation-fibrogenesis showed positive effects, there were favorable trends for histology with the strongest to reduce and prevent worsening of fibrosis,” Harrison said. “These results are very promising, and the next steps include a pivotal trail design and dose selection.” Read more about

HistoIndex Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

HistoIndex Rank

HistoIndex Frequently Asked Questions (FAQ)

  • Where is HistoIndex's headquarters?

    HistoIndex's headquarters is located at 79 Ayer Rajah Crescent, Singapore.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.